Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Axonal Degeneration in Tauopathies: Disease Relevance and Underlying Mechanisms.

Kneynsberg A, Combs B, Christensen K, Morfini G, Kanaan NM.

Front Neurosci. 2017 Oct 17;11:572. doi: 10.3389/fnins.2017.00572. eCollection 2017. Review.

2.

Aging Does Not Affect Axon Initial Segment Structure and Somatic Localization of Tau Protein in Hippocampal Neurons of Fischer 344 Rats.

Kneynsberg A, Kanaan NM.

eNeuro. 2017 Jul 21;4(4). pii: ENEURO.0043-17.2017. doi: 10.1523/ENEURO.0043-17.2017. eCollection 2017 Jul-Aug.

3.

Quantitative and semi-quantitative measurements of axonal degeneration in tissue and primary neuron cultures.

Kneynsberg A, Collier TJ, Manfredsson FP, Kanaan NM.

J Neurosci Methods. 2016 Jun 15;266:32-41. doi: 10.1016/j.jneumeth.2016.03.004. Epub 2016 Mar 28.

4.

Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Combs B, Kneynsberg A, Kanaan NM.

Methods Mol Biol. 2016;1382:339-66. doi: 10.1007/978-1-4939-3271-9_25.

5.

A method for combining RNAscope in situ hybridization with immunohistochemistry in thick free-floating brain sections and primary neuronal cultures.

Grabinski TM, Kneynsberg A, Manfredsson FP, Kanaan NM.

PLoS One. 2015 Mar 20;10(3):e0120120. doi: 10.1371/journal.pone.0120120. eCollection 2015.

6.

Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.

Kumar A, Kneynsberg A, Tucholski J, Perry G, van Groen T, Detloff PJ, Lesort M.

Exp Neurol. 2012 Sep;237(1):78-89. doi: 10.1016/j.expneurol.2012.05.015. Epub 2012 Jun 12.

7.

Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease.

Perry GM, Tallaksen-Greene S, Kumar A, Heng MY, Kneynsberg A, van Groen T, Detloff PJ, Albin RL, Lesort M.

Hum Mol Genet. 2010 Sep 1;19(17):3354-71. doi: 10.1093/hmg/ddq247. Epub 2010 Jun 17.

Supplemental Content

Loading ...
Support Center